文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Liposomes as versatile agents for the management of traumatic and nontraumatic central nervous system disorders: drug stability, targeting efficiency, and safety.

作者信息

Zhang Mingyu, Xiang Chunyu, Niu Renrui, He Xiaodong, Luo Wenqi, Liu Wanguo, Gu Rui

机构信息

Department of Orthopedic Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China.

出版信息

Neural Regen Res. 2025 Jul 1;20(7):1883-1899. doi: 10.4103/NRR.NRR-D-24-00048. Epub 2024 Jul 10.


DOI:10.4103/NRR.NRR-D-24-00048
PMID:39254548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11691476/
Abstract

Various nanoparticle-based drug delivery systems for the treatment of neurological disorders have been widely studied. However, their inability to cross the blood-brain barrier hampers the clinical translation of these therapeutic strategies. Liposomes are nanoparticles composed of lipid bilayers, which can effectively encapsulate drugs and improve drug delivery across the blood-brain barrier and into brain tissue through their targeting and permeability. Therefore, they can potentially treat traumatic and nontraumatic central nervous system diseases. In this review, we outlined the common properties and preparation methods of liposomes, including thin-film hydration, reverse-phase evaporation, solvent injection techniques, detergent removal methods, and microfluidics techniques. Afterwards, we comprehensively discussed the current applications of liposomes in central nervous system diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, and brain tumors. Most studies related to liposomes are still in the laboratory stage and have not yet entered clinical trials. Additionally, their application as drug delivery systems in clinical practice faces challenges such as drug stability, targeting efficiency, and safety. Therefore, we proposed development strategies related to liposomes to further promote their development in neurological disease research.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/7774c85e1b4d/NRR-20-1883-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/6ee147a064b6/NRR-20-1883-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/77b9d7496f41/NRR-20-1883-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/eaa2db630805/NRR-20-1883-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/3d27cf1b9567/NRR-20-1883-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/1c275201fc58/NRR-20-1883-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/2eb0e7ba6f9d/NRR-20-1883-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/218823320b93/NRR-20-1883-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/92ea2531c7c7/NRR-20-1883-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/7774c85e1b4d/NRR-20-1883-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/6ee147a064b6/NRR-20-1883-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/77b9d7496f41/NRR-20-1883-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/eaa2db630805/NRR-20-1883-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/3d27cf1b9567/NRR-20-1883-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/1c275201fc58/NRR-20-1883-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/2eb0e7ba6f9d/NRR-20-1883-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/218823320b93/NRR-20-1883-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/92ea2531c7c7/NRR-20-1883-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f06d/11691476/7774c85e1b4d/NRR-20-1883-g009.jpg

相似文献

[1]
Liposomes as versatile agents for the management of traumatic and nontraumatic central nervous system disorders: drug stability, targeting efficiency, and safety.

Neural Regen Res. 2025-7-1

[2]
Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders.

Neurochem Res. 2022-3

[3]
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases.

J Control Release. 2025-5-10

[4]
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.

Int J Mol Sci. 2020-8-23

[5]
Nanotechnology-based drug delivery for central nervous system disorders.

Biomed Pharmacother. 2021-11

[6]
Nose to Brain: Exploring the Progress of Intranasal Delivery of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers.

Int J Nanomedicine. 2024

[7]
Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies.

Cureus. 2024-9-1

[8]
Therapeutic nanoplatforms and delivery strategies for neurological disorders.

Nano Converg. 2018-11-30

[9]
Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders.

Nanomaterials (Basel). 2022-6-22

[10]
Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.

CNS Neurol Disord Drug Targets. 2024

引用本文的文献

[1]
Plant-derived exosome-like nanovesicles: mechanisms and molecular understanding in neurological disorders with potential therapeutic applications.

Drug Deliv Transl Res. 2025-8-20

[2]
Brain Endothelial Cells in Blood-Brain Barrier Regulation and Neurological Therapy.

Int J Mol Sci. 2025-6-18

本文引用的文献

[1]
Isoform- and cell-state-specific APOE homeostasis and function.

Neural Regen Res. 2024-11-1

[2]
Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury.

J Control Release. 2023-12

[3]
Aromatized liposomes for sustained drug delivery.

Nat Commun. 2023-10-20

[4]
Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease.

Adv Mater. 2023-12

[5]
Ferroptosis in Parkinson's disease: Molecular mechanisms and therapeutic potential.

Ageing Res Rev. 2023-11

[6]
Olfactory dysfunction and its related molecular mechanisms in Parkinson's disease.

Neural Regen Res. 2024-3

[7]
Smart Liposomal Nanocarrier Enhanced the Treatment of Ischemic Stroke through Neutrophil Extracellular Traps and Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase-Stimulator of Interferon Genes (cGAS-STING) Pathway Inhibition of Ischemic Penumbra.

ACS Nano. 2023-9-26

[8]
A Comparative Study about the Neuroprotective Effects of DHA-Enriched Phosphatidylserine and EPA-Enriched Phosphatidylserine against Oxidative Damage in Primary Hippocampal Neurons.

Mar Drugs. 2023-7-19

[9]
A review of the neurotransmitter system associated with cognitive function of the cerebellum in Parkinson's disease.

Neural Regen Res. 2024-2

[10]
Advantages of nanocarriers for basic research in the field of traumatic brain injury.

Neural Regen Res. 2024-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索